Immunovant (NASDAQ: IMVT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Immunovant reported 62 open-market sales of 509,947 shares ($16.5m) and 1 open-market purchase of 16,666,666 shares ($350.0m), by 10 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 28 October 2026 | Girao Tiago | Chief Financial Officer | Open-market sale | −6,606 | $28.50 | 234,192 | Form 4 |
| 21 October 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −2,595 | $28.94 | 198,937 | Form 4 |
| 7 October 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −2,213 | $32.06 | 203,128 | Form 4 |
| 7 October 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −1,596 | $32.06 | 201,532 | Form 4 |
| 7 October 2026 | Gloria Melanie | Chief Operating Officer | Open-market sale | −2,241 | $32.06 | 217,060 | Form 4 |
| 7 October 2026 | Van Tuyl Christopher | Chief Legal Officer | Open-market sale | −1,327 | $32.06 | 175,218 | Form 4 |
| 2 October 2026 | Venker Eric | Chief Executive Officer | Open-market sale | −3,506 | $34.11 | 257,075 | Form 4 |
| 1 October 2026 | Venker Eric | Chief Executive Officer | Option exercise | +92,187 | $14.46 | 346,467 | Form 4 |
| 1 October 2026 | Venker Eric | Chief Executive Officer | Returned to the company | −85,886 | $33.65 | 260,581 | Form 4 |
| 23 September 2026 | Van Tuyl Christopher | Chief Legal Officer | Open-market sale | −2,846 | $36.36 | 176,545 | Form 4 |
| 28 August 2026 | Pande Atul | Director | Option exercise, 10b5-1 plan | +1,500 | $8.43 | 118,231 | Form 4 |
| 28 August 2026 | Pande Atul | Director | Open-market sale, 10b5-1 plan | −1,500 | $43.27 | 116,731 | Form 4 |
| 20 August 2026 | Gloria Melanie | Chief Operating Officer | Open-market sale | −3,056 | $44.16 | 219,301 | Form 4 |
| 24 July 2026 | Pande Atul | Director | Option exercise, 10b5-1 plan | +1,500 | $8.43 | 118,231 | Form 4 |
| 24 July 2026 | Pande Atul | Director | Open-market sale, 10b5-1 plan | −1,500 | $39.80 | 116,731 | Form 4 |
| 23 July 2026 | Girao Tiago | Chief Financial Officer | Open-market sale | −6,798 | $38.69 | 240,798 | Form 4 |
| 23 July 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −2,857 | $38.69 | 205,341 | Form 4 |
| 8 July 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −1,906 | $39.53 | 209,779 | Form 4 |
| 8 July 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −105 | $39.99 | 209,674 | Form 4 |
| 8 July 2026 | Stout Jay S | Chief Technology Officer | Open-market sale | −1,399 | $39.53 | 208,275 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Immunovant page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.